A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients

BACKGROUND: Secondary hyperparathyroidism (SHPT) is a major complication associated with chronic kidney disease. We evaluated the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, in Japanese haemodialysis patients with SHPT. METHODS: In this phase 3, multice...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukagawa, Masafumi, Yokoyama, Keitaro, Shigematsu, Takashi, Akiba, Takashi, Fujii, Akifumi, Kuramoto, Takuto, Odani, Motoi, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837215/
https://www.ncbi.nlm.nih.gov/pubmed/28057872
http://dx.doi.org/10.1093/ndt/gfw408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837215/
https://www.ncbi.nlm.nih.gov/pubmed/28057872
http://dx.doi.org/10.1093/ndt/gfw408

Ejemplares similares